Kiniksa Pharmaceuticals, Ltd. (KNSA) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$56.93
Price Target
$64.00
Target Range
$59.00 — $71.00
Analyst Rating
Buy
Forward P/E41.6x
Trailing P/E75.9x
Forward PEG—
Implied Growth+54.5%
Median Target$62.00
Analyst Spread18.8%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$59
+3.6%
Consensus
$64
+12.4%
Bull Case
$71
+24.7%
KNSA Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Kiniksa Pharmaceuticals, Ltd. (KNSA) has a Wall Street consensus price target of $64.00, based on estimates from 11 covering analysts. With the stock currently trading at $56.93, this represents a potential upside of +12.4%. The company has a market capitalization of $4.22B.
Analyst price targets range from a low of $59.00 to a high of $71.00, representing a 19% spread in expectations. The median target of $62.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, KNSA trades at a trailing P/E of 75.9x and forward P/E of 41.6x. Analysts expect EPS to grow +54.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+72.5%
Avg Forward P/E18.9x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ARDXArdelyx, Inc. | $1.7B | $6.98 | $17.00 | +143.6% | Buy | — | 16 |
 PRAXPraxis Precision Medicines, Inc. | $9.6B | $333.28 | $544.40 | +63.3% | Buy | — | 16 |
 RCUSArcus Biosciences, Inc. | $2.5B | $24.80 | $30.00 | +21.0% | Buy | — | 18 |
 IMVTImmunovant, Inc. | $5.5B | $27.22 | $45.50 | +67.2% | Buy | — | 23 |
 CABACabaletta Bio, Inc. | $409M | $4.00 | $16.33 | +308.3% | Buy | — | 12 |
 RAREUltragenyx Pharmaceutical Inc. | $2.6B | $26.13 | $51.50 | +97.1% | Buy | — | 33 |
 AMRNAmarin Corporation plc | $309M | $14.84 | $2.17 | -85.4% | Hold | — | 18 |
 INVAInnoviva, Inc. | $1.9B | $22.80 | $37.67 | +65.2% | Buy | 11.9x | 10 |
 PTGXProtagonist Therapeutics, Inc. | $6.4B | $98.85 | $116.75 | +18.1% | Buy | 30.6x | 26 |
 IQVIQVIA Holdings Inc. | $30.3B | $178.64 | $225.63 | +26.3% | Buy | 14.1x | 44 |
Upside Potential Comparison
CABAARDXRAREIMVTINVAPRAXIQVRCUSSee KNSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KNSA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KNSA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKNSA — Frequently Asked Questions
Quick answers to the most common questions about buying KNSA stock.
What is the KNSA stock price target for 2026?
Kiniksa Pharmaceuticals, Ltd. (KNSA) has a consensus 12-month price target of $64, implying 12.4% upside from $56.93. The 11 analysts covering KNSA see moderate appreciation potential.
Is KNSA a buy, sell, or hold?
KNSA has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $64 implies 12.4% upside from current levels.
Is KNSA stock overvalued or undervalued?
At a forward P/E of 41.5638x, KNSA trades at a premium valuation. The consensus price target of $64 (12.4% upside) suggests analysts still see growth justifying the multiple.
How high can KNSA stock go?
The most bullish Wall Street analyst has a price target of $71 for KNSA, while the most conservative target is $59. The consensus of $64 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover KNSA stock?
KNSA is moderately covered, with 11 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the KNSA stock forecast?
The 12-month KNSA stock forecast based on 11 Wall Street analysts shows a consensus price target of $64, with estimates ranging from $59 (bear case) to $71 (bull case). The median consensus rating is "Buy".
What is KNSA's forward P/E ratio?
KNSA trades at a forward P/E ratio of 41.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 75.9x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy KNSA stock?
Wall Street analysts are optimistic on KNSA, with a "Buy" consensus rating and $64 price target (12.4% upside). 11 of 11 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do KNSA price targets vary so much?
KNSA analyst price targets range from $59 to $71, a 19% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $64 consensus represents the middle ground.